These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]
5. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262 [TBL] [Abstract][Full Text] [Related]
6. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J; Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758 [TBL] [Abstract][Full Text] [Related]
7. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945 [TBL] [Abstract][Full Text] [Related]
8. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
9. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
10. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema. Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095 [TBL] [Abstract][Full Text] [Related]
11. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years. Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754 [TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period. Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812 [TBL] [Abstract][Full Text] [Related]
13. Vitrectomy Combined with Intraoperative Dexamethasone Implant for the Management of Refractory Diabetic Macular Edema. Kim KT; Jang JW; Kang SW; Chae JB; Cho K; Bae K Korean J Ophthalmol; 2019 Jun; 33(3):249-258. PubMed ID: 31179656 [TBL] [Abstract][Full Text] [Related]
14. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant. Pessoa B; Ferreira A; Leite J; Figueira J; Meireles A; Beirão JM Ophthalmic Res; 2021; 64(4):639-647. PubMed ID: 33601389 [TBL] [Abstract][Full Text] [Related]
15. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Adams OE; Schechet SA; Hariprasad SM Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
17. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN Panos GD; Arruti N; Patra S Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704 [TBL] [Abstract][Full Text] [Related]
18. CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA. Chakravarthy U; Yang Y; Lotery A; Ghanchi F; Bailey C; Holz FG; Downey L; Weber M; Eter N; Dugel PU Retina; 2018 Feb; 38(2):343-351. PubMed ID: 28257378 [TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema. Chen YY; Chen PY; Chen FT; Chen YJ; Wang JK Int Ophthalmol; 2018 Feb; 38(1):293-299. PubMed ID: 28176171 [TBL] [Abstract][Full Text] [Related]
20. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]